Company Profile
Cyclerion Stock Price, News & Analysis
- Ticker:
- CYCN
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
3.50 USD (0.00%)
Close
Last updated: July 27, 2026
13.1M USD
Market cap
Why the stock is moving
As of Jul 27, 2026, CYCN was little changed and closed at $3.50. No new same-company headline was identified in the current news window.
Company overview
Business overview
Cyclerion was a biotechnology company focused on cyclic nucleotide biology and central nervous system or vascular-related disease programs before becoming a historical ticker. Its story reflected the challenge of turning a mechanistic platform into a durable drug franchise.
Geographic Base and Sector Classification
Cyclerion was headquartered in the United States and traded on NASDAQ. It sat in the development-stage biotechnology segment.
Business Model Characteristics
The business depended on clinical validation, strategic focus, and capital efficiency. Investors historically watched whether the platform could produce differentiated medicines in a difficult field.
Position Within the Biotechnology Landscape
Cyclerion belongs to the historical platform-biotech set. Like many early scientific names, its stock depended on data and the market's patience for development risk.
Future catalysts
Cyclerion is now largely a legacy and closeout story, so the catalysts are any strategic or asset-disposition update rather than a live pipeline event. The market is mainly waiting for clarity on remaining value.
Recent news
The five most recent related feed items are shown below in reverse chronological order.
- 01
BrainStorm Appoints Former FDA Associate Commissioner Peter J. Pitts as Executive Chairman
BCLI · Source: Brainstorm Cell Therapeutics Inc.
- 02
Denali Therapeutics to Report Second Quarter 2026 Financial Results and Business Highlights on August 6, 2026
DNLI · Source: Denali Therapeutics
- 03
Tonix Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 10, 2026
TNXP · Source: Tonix Pharmaceuticals
- 04
Inhibikase Therapeutics Announces FDA Orphan Drug Designation Granted to IKT-001 for the Treatment of PAH
IKT · Source: Inhibikase Therapeutics
- 05
Pasithea Therapeutics Announces Presentation of PAS-004 Data to European Society for Medical Oncology (ESMO) Congress 2026
KTTA · Source: Pasithea Therapeutics
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Cyclerion (CYCN)?
Cyclerion (CYCN) most recently closed at 3.50 USD, a 0.00% move versus the previous session.
What is the market cap of Cyclerion (CYCN)?
Cyclerion currently has a market capitalization of 13.1M USD on BioPharmSignal.
What does Cyclerion do?
Cyclerion was a biotechnology company focused on cyclic nucleotide biology and central nervous system or vascular-related disease programs before becoming a historical ticker. Its story reflected the challenge of turning a mechanistic platform into a durable drug franchise.
On which exchange is CYCN stock listed?
Cyclerion (CYCN) is associated with NASDAQ, United States, Biopharma.
What is Cyclerion?
Cyclerion is now largely a legacy and closeout story, so the catalysts are any strategic or asset-disposition update rather than a live pipeline event.
Which conditions is Cyclerion targeting with Cyclerion?
Cyclerion is now largely a legacy and closeout story, so the catalysts are any strategic or asset-disposition update rather than a live pipeline event.
How does Cyclerion describe recent progress with Cyclerion?
Cyclerion is now largely a legacy and closeout story, so the catalysts are any strategic or asset-disposition update rather than a live pipeline event.
What future catalysts are investors watching for Cyclerion?
Cyclerion is now largely a legacy and closeout story, so the catalysts are any strategic or asset-disposition update rather than a live pipeline event. The market is mainly waiting for clarity on remaining value.